37 Results

People

  1. Chapman
    Chapman
  2. Konner
    Konner
  3. Abrey
    Abrey
  4. Dickson
    Dickson
  5. Gounder
    Gounder
  6. Grimm
    Grimm
  7. Lendvai
    Lendvai
  8. Marr
    Marr
  9. Younes
    Younes
  10. Abou-Alfa
    Abou-Alfa

Groups

  1. Department of Medicine (24)
  2. Solid Tumor Oncology Division (19)
  3. Center for Hematologic Malignancies (6)
  4. Hematologic Malignancies, Division of (6)
  5. Surgery (6)
  6. Gynecology Disease Management Team (5)
  7. GDMT, Medicine (4)
  8. Gastrointestinal Oncology Service (4)
  9. Gynecologic Medicine Service (4)
  10. Sloan Kettering Institute Postdocs (4)
  1. "blurred vision"
  2. "Journal article"
Formats
  1. Journal Article (37)
Groups
  1. Department of Medicine (24)
  2. Solid Tumor Oncology Division (19)
  3. Center for Hematologic Malignancies (6)
  4. Hematologic Malignancies, Division of (6)
  5. Surgery (6)
  6. Gynecology Disease Management Team (5)

More Groups

People
  1. Jason Konner (3)
  2. Paul Chapman (3)
  3. Anas Younes (2)
  4. Brian Marr (2)
  5. Lauren Abrey (2)
  6. Mark Dickson (2)

More People

Years
  1. 2023 (1)
  2. 2022 (3)
  3. 2021 (1)
  4. 2020 (3)
  5. 2019 (2)
  6. 2018 (3)

More Years

Publications
  1. Clinical Cancer Research (4)
  2. Journal of Clinical Oncology (3)
  3. Lancet Oncology (3)
  4. American Journal of Ophthalmology Case Reports (2)
  5. Gynecologic Oncology (2)
  6. Advances in Pharmacology (1)

More Publications

Publishers
  1. Elsevier Inc. (8)
  2. American Association for Cancer Research (4)
  3. American Society of Clinical Oncology (4)
  4. Elsevier Science, Inc. (4)
  5. Nature Publishing Group (2)
  6. Oxford University Press (2)

More Publishers

Results (37)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial
    Journal Article

    Nooka, A. K.; Cohen, A. D.; Lee, H. C.; Badros, A.; Suvannasankha, A.; Callander, N.; Abdallah, A. O.; Trudel, S.; Chari, A.; Libby, E. N.; more...
    Cancer (2023)

    Fulltext@MSK | Save
  • Bendamustine in combination with ofatumumab as first line treatment for elderly patients with mantle cell lymphoma: A phase II risk-adapted design
    Journal Article

    Kumar, A.; Casulo, C.; Joffe, E.; Moskowitz, C.; Gerecitano, J.; Moskowitz, A.; Younes, A.; Drullinsky, P.; Drill, E.; Choma, M.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Selinexor in advanced, metastatic dedifferentiated liposarcoma: A multinational, randomized, double-blind, placebo-controlled trial
    Journal Article

    Gounder, M. M.; Razak, A. A.; Somaiah, N.; Chawla, S.; Martin-Broto, J.; Grignani, G.; Schuetze, S. M.; Vincenzi, B.; Wagner, A. J.; Chmielowski, B.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Central retinal vein occlusion in the setting of fibroblast growth factor receptor inhibition
    Journal Article

    Foulsham, W.; Edghill, B. Z.; Canestraro, O. D. J.; Makker, V.; Konner, J.; Abramson, D. H.; Francis, J. H.
    American Journal of Ophthalmology Case Reports (2022)

    Fulltext@MSK | Save
  • CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: An open-label, multicentre, phase 1b study
    Journal Article

    O'Hara, M. H.; O'Reilly, E. M.; Varadhachary, G.; Wolff, R. A.; Wainberg, Z. A.; Ko, A. H.; Fisher, G.; Rahma, O.; Lyman, J. P.; Cabanski, C. R.; more...
    Lancet Oncology (2021)

    Fulltext@MSK | Save
  • Necrotizing myositis in a rectus muscle arising in the setting of long-standing Langerhans cell histiocystosis and recent dabrafenib treatment
    Journal Article

    van Landingham, S. W.; Puccetti, D.; Potter, H.; Gamm, D.; Diamond, E. L.; Lucarelli, M. J.
    American Journal of Ophthalmology Case Reports (2020)

    Fulltext@MSK | Save
  • Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia
    Journal Article

    Shah, N. N.; Bhojwani, D.; August, K.; Baruchel, A.; Bertrand, Y.; Boklan, J.; Dalla-Pozza, L.; Dennis, R.; Hijiya, N.; Locatelli, F.; more...
    Pediatric Blood and Cancer (2020)

    Fulltext@MSK | Save
  • Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomised, open-label, phase 2 study
    Journal Article

    Lonial, S.; Lee, H. C.; Badros, A.; Trudel, S.; Nooka, A. K.; Chari, A.; Abdallah, A. O.; Callander, N.; Lendvai, N.; Sborov, D.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • Combined PIK3CA and FGFR inhibition with alpelisib and infigratinib in patients with PIK3CA-mutant solid tumors, with or without FGFR alterations
    Journal Article

    Hyman, D. M.; Tran, B.; Paz-Ares, L.; Machiels, J. P.; Schellens, J. H.; Bedard, P. L.; Campone, M.; Cassier, P. A.; Sarantopoulos, J.; Vaishampayan, U.; more...
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save
  • Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: An update on safety and efficacy from dose expansion phase I study
    Journal Article

    Trudel, S.; Lendvai, N.; Popat, R.; Voorhees, P. M.; Reeves, B.; Libby, E. N.; Richardson, P. G.; Hoos, A.; Gupta, I.; Bragulat, V.; more...
    Blood Cancer Journal (2019)

    Fulltext@MSK | Save